Explosive seems like the only word that adequately describes Trillium Therapeutics’ (TRIL) gains in 2020. The immuno-oncology company has taken off on an upward trajectory, and is up by a whopping 833% year-to-date. However, over the last few days, shares have experienced a pullback. Does the sell-off indicate the tides are turning?No, says JonesTrading’s Soumit Roy. In fact, the five-star analyst argues any weakness presents investors with a chance to get in on the action.What exactly is behind his bullish thesis? Part of Roy’s excitement is related to I-Mab’s recently announced partnership with AbbVie. The agreement, which will see AbbVie …read more
Source:: Yahoo Finance
